

ASSIGNMENT

Patrick ANDRE, residing at 287 Taylor Road South, Short Hills, NJ 07078, USA **Chun CHEN**, residing at 727 San Pablo Avenue, Unit 202, Albany, CA 94706, USA and **Scott TURNER**, residing in Oakland, CA, USA (each referred to as “Assignor”) have made an invention(s) (the “Invention(s)”) set forth in the following applications for patent of the United States, all entitled **COMPOSITIONS AND METHODS FOR ACTIVATION OF INTEGRINS**, and which are:

U.S. provisional application bearing Application No. 62/935,732 and filed on November 15, 2019;

U.S. provisional application bearing Application No. 63/009,020 and filed on April 13, 2020; and

U.S. provisional application bearing Application No. 63/029,070 and filed on May 22, 2020;

WHEREAS, PLIANT THERAPEUTICS, INC., a corporation having its principal place of business at 260 Littlefield Avenue, South San Francisco, CA 94080, (the “Assignee”), its successors, legal representatives and assigns, is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified above; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any and all patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor’s entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application(s) for patent identified above;
- (c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the

Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;

(d) any application(s) for patent of the United States or other countries claiming the Invention(s);

(e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any priority application(s), substitute application(s), division(s), continuation(s), and continuation(s)-in-part;

(f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and

(g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.


The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the

Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.


The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

The Assignor and Assignee understand that electronic signatures are acceptable and that, by signing electronically, signatories agree to the use of electronic signatures.

Date: November 3 2020

By: 
Patrick Andre


Witness:


Signature

11/09/20
Date

Jean-Baptiste Andre
Printed name

Witness:


Signature


11/09/20
Date

Valérie Sarnier
Printed name

Date: 11/11/2020

By: 
Chun Chen


Witness:


Signature

11/11/2020
Date

Nuo Chen
Printed name

Witness:


Signature

11/11/2020
Date

Qin Xu
Printed name

Date: 11/13/2020

By: 

Scott Turner

Witness:


Signature

11/13/2020

Date

Johanna Schaub
Printed name

Witness:


Signature

11/13/2020

Date

Johannes Hull
Printed name

For and on behalf of ASSIGNEE:

Date: November 13, 2020

By: Johannes Gull
Name: Johannes Gull
Title: Chief Business Officer
Company: Pliant Therapeutics, Inc.

Witness:

Johanna Schaub
Signature

11/13/2020
Date

Johanna Schaub
Printed name

Witness:

Scott Turner
Signature

11/13/2020
Date

Scott Turner
Printed name